Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024036714> ?p ?o ?g. }
- W2024036714 endingPage "372" @default.
- W2024036714 startingPage "369" @default.
- W2024036714 abstract "We investigated whether 5 to 20mg per week oral methotrexate could slow down disease progression in 44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks. Mean change of quantitative muscle strength testing sum scores was the primary study outcome measure. Quantitative muscle strength testing sum scores declined in both treatment groups, -0.2% for methotrexate and -3.4% for placebo (95% confidence interval = -2.5% to +9.1% for difference). There were also no differences in manual muscle testing sum scores, activity scale scores and patients' own assessments after 48 weeks of treatment. Serum creatine kinase activity decreased significantly in the methotrexate group. We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity." @default.
- W2024036714 created "2016-06-24" @default.
- W2024036714 creator A5004818554 @default.
- W2024036714 creator A5017804716 @default.
- W2024036714 creator A5018600066 @default.
- W2024036714 creator A5031155343 @default.
- W2024036714 creator A5034136074 @default.
- W2024036714 creator A5037368893 @default.
- W2024036714 creator A5039941295 @default.
- W2024036714 creator A5041474139 @default.
- W2024036714 creator A5051056050 @default.
- W2024036714 creator A5052424289 @default.
- W2024036714 creator A5055079427 @default.
- W2024036714 creator A5056240427 @default.
- W2024036714 creator A5068004849 @default.
- W2024036714 creator A5072004949 @default.
- W2024036714 creator A5072736652 @default.
- W2024036714 creator A5080250731 @default.
- W2024036714 creator A5084875653 @default.
- W2024036714 date "2002-02-27" @default.
- W2024036714 modified "2023-09-30" @default.
- W2024036714 title "Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo" @default.
- W2024036714 cites W1970850123 @default.
- W2024036714 cites W1984028130 @default.
- W2024036714 cites W1985693809 @default.
- W2024036714 cites W2011408110 @default.
- W2024036714 cites W2020968569 @default.
- W2024036714 cites W2037223188 @default.
- W2024036714 cites W2056138384 @default.
- W2024036714 cites W2060093283 @default.
- W2024036714 cites W2064041290 @default.
- W2024036714 cites W2074203661 @default.
- W2024036714 cites W2119981808 @default.
- W2024036714 cites W2136430968 @default.
- W2024036714 doi "https://doi.org/10.1002/ana.10121" @default.
- W2024036714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11891832" @default.
- W2024036714 hasPublicationYear "2002" @default.
- W2024036714 type Work @default.
- W2024036714 sameAs 2024036714 @default.
- W2024036714 citedByCount "116" @default.
- W2024036714 countsByYear W20240367142012 @default.
- W2024036714 countsByYear W20240367142013 @default.
- W2024036714 countsByYear W20240367142014 @default.
- W2024036714 countsByYear W20240367142015 @default.
- W2024036714 countsByYear W20240367142016 @default.
- W2024036714 countsByYear W20240367142017 @default.
- W2024036714 countsByYear W20240367142018 @default.
- W2024036714 countsByYear W20240367142019 @default.
- W2024036714 countsByYear W20240367142020 @default.
- W2024036714 countsByYear W20240367142021 @default.
- W2024036714 countsByYear W20240367142022 @default.
- W2024036714 countsByYear W20240367142023 @default.
- W2024036714 crossrefType "journal-article" @default.
- W2024036714 hasAuthorship W2024036714A5004818554 @default.
- W2024036714 hasAuthorship W2024036714A5017804716 @default.
- W2024036714 hasAuthorship W2024036714A5018600066 @default.
- W2024036714 hasAuthorship W2024036714A5031155343 @default.
- W2024036714 hasAuthorship W2024036714A5034136074 @default.
- W2024036714 hasAuthorship W2024036714A5037368893 @default.
- W2024036714 hasAuthorship W2024036714A5039941295 @default.
- W2024036714 hasAuthorship W2024036714A5041474139 @default.
- W2024036714 hasAuthorship W2024036714A5051056050 @default.
- W2024036714 hasAuthorship W2024036714A5052424289 @default.
- W2024036714 hasAuthorship W2024036714A5055079427 @default.
- W2024036714 hasAuthorship W2024036714A5056240427 @default.
- W2024036714 hasAuthorship W2024036714A5068004849 @default.
- W2024036714 hasAuthorship W2024036714A5072004949 @default.
- W2024036714 hasAuthorship W2024036714A5072736652 @default.
- W2024036714 hasAuthorship W2024036714A5080250731 @default.
- W2024036714 hasAuthorship W2024036714A5084875653 @default.
- W2024036714 hasConcept C126322002 @default.
- W2024036714 hasConcept C141071460 @default.
- W2024036714 hasConcept C142724271 @default.
- W2024036714 hasConcept C1862650 @default.
- W2024036714 hasConcept C204787440 @default.
- W2024036714 hasConcept C27081682 @default.
- W2024036714 hasConcept C2776418732 @default.
- W2024036714 hasConcept C2777327098 @default.
- W2024036714 hasConcept C2780247198 @default.
- W2024036714 hasConcept C2781059491 @default.
- W2024036714 hasConcept C2781232998 @default.
- W2024036714 hasConcept C36880943 @default.
- W2024036714 hasConcept C44249647 @default.
- W2024036714 hasConcept C71924100 @default.
- W2024036714 hasConcept C90924648 @default.
- W2024036714 hasConceptScore W2024036714C126322002 @default.
- W2024036714 hasConceptScore W2024036714C141071460 @default.
- W2024036714 hasConceptScore W2024036714C142724271 @default.
- W2024036714 hasConceptScore W2024036714C1862650 @default.
- W2024036714 hasConceptScore W2024036714C204787440 @default.
- W2024036714 hasConceptScore W2024036714C27081682 @default.
- W2024036714 hasConceptScore W2024036714C2776418732 @default.
- W2024036714 hasConceptScore W2024036714C2777327098 @default.
- W2024036714 hasConceptScore W2024036714C2780247198 @default.
- W2024036714 hasConceptScore W2024036714C2781059491 @default.
- W2024036714 hasConceptScore W2024036714C2781232998 @default.
- W2024036714 hasConceptScore W2024036714C36880943 @default.
- W2024036714 hasConceptScore W2024036714C44249647 @default.